T inducer of cytochrome P450 enzymes and is less likely to reduce concentrations of coadministered PIs, it is not yet widely available in developing countries, though access is rapidly expanding [22]. Further, RBT (and its main metabolite) are substrates of CYP3A, [23] leading to bidirectional drug interactions with PIs. For example, giving RTV, a potent inhibitor of CYP3A, together with RBT incre